stockportfolio.pro
BSX vs CAH: Which Stock Is the Better Buy?
Boston Scientific Corporation and Cardinal Health, Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
AI verdict — BSX vs CAH, read from the filings
The stronger business, the cheaper stock, and the risks — synthesised from both companies’ SEC filings, every figure computed not guessed. Not investment advice.
| Boston Scientific Corporation (BSX) | Cardinal Health, Inc. (CAH) | |
|---|---|---|
| Market cap | $67.1B | $56.0B |
| Revenue (latest FY) | $20.07B | $222.58B |
| Net income (latest FY) | $2.90B | $1.56B |
| Revenue growth (5y CAGR) | 15.2% | 7.8% |
| Net margin | 14.4% | 0.7% |
| Return on equity | 12.0% | -56.1% |
| P/E ratio | 18.9 | 36.5 |
| Dividend yield | — | 0.9% |
| Profitable years (of last 10) | 9 | 8 |
| Positive free cash flow | Yes | Yes |
See the full BSX vs CAH breakdown
Both companies across 19 years of income statement, balance sheet and cash flow — with ratios, health checks and Ask, the SEC-grounded research assistant. Free, no account needed.
Open BSX's full financials → Open CAH's full financials →Frequently asked questions
Which is bigger, BSX or CAH?
Boston Scientific Corporation is larger by market capitalization — $67.1B versus $56.0B.
Which grows faster, BSX or CAH?
Over the last five fiscal years, Boston Scientific Corporation grew revenue faster — 15.2%/yr versus 7.8%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.
Keep exploring
BSX fundamentals → · CAH fundamentals → · All 1,500+ companies → · Free screener →